Molecular Biology

, Volume 51, Issue 6, pp 855–864 | Cite as

A Method for the Parallel and Sequential Generation of Single-Domain Antibodies for the Proteomic Analysis of Human Blood Plasma

  • O. S. Goryainova
  • T. I. Ivanova
  • M. V. Rutovskaya
  • S. V. Tillib
Current Trends in the Application of Monoclonal Antibodies Special Issue


A new efficient method for the parallel and sequential stepwise generation of single-domain antibodies to various high-abundance human-plasma proteins has been described. Single-domain antibodies have a number of features that favorably distinguish them from classical antibodies. In particular, they are able to recognize unusual unique conformational epitopes of native target proteins, small in size, and relatively easily produced and modified; have enhanced stability; and rapidly renature after denaturation. As a consequence, the immunosorbents that utilize these antibodies can be reused without any significant loss of activity. The principal novelty and universality of the described method is that it enables the sequential generation of antibodies to a number of high-abundance and yet unknown antigens of a complex protein mixture without the need for purified antigens. The effectiveness of the method is demonstrated by the example of generation of single-domain antibodies to a number of high-abundance proteins of the human blood plasma. The produced antibodies are promising biotechnological tools that can be used to develop prototypes for new diagnostic and therapeutic agents, as well as appropriate immunoaffinity-based methods for removal, enrichment, analysis, and/or targeting of specified proteins and their complexes from (in) the human blood. As we show, the generated single-domain antibodies can be efficiently used in designing new immunosorbents. As a rule, commercially available analogous immunosorbents that utilize classical antibodies remove many major proteins from the blood plasma immediately, while immunosorbents for many individual proteins are difficult to find and rather expensive. Single-domain antibodies generated by our method are unique new materials that allow for the development of more efficient and delicate approaches to pretreatment of plasma and the analysis of various blood plasma biomarkers.


recombinant single-domain antibody immunosorbent high-abundance blood-plasma protein 



serum albumin


immunoglobulin A


immunoglobulin G


immunoglobulin M




carcinoembryonic antigen.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Berezov T.T., Korovkin B.F. 1998. Biologicheskaya khimiya. Uchebnik (A Textbook in Biochemistry), 3rd ed. Moscow: Meditsina. ISBN 5-225-02709-1.Google Scholar
  2. 2.
    Anderson L. 2014. Six decades searching for meaning in the proteome. J. Proteomics. 107, 24–30.CrossRefPubMedGoogle Scholar
  3. 3.
    Geyer P.E., Kulak N.A., Pichler G., et al. 2016. Plasma proteome profiling to assess human health and disease. Cell Systems. 2, 185–195.CrossRefPubMedGoogle Scholar
  4. 4.
    Prieto D.A., Johann D.J., Wei B.R., et al. 2014. Mass spectrometry in cancer biomarker research: A case for immunodepletion of abundant blood-derived proteins from clinical tissue specimens. Biomark. Med. 8, 269–286.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Keshishian H., Burgess M.W., Gillette M.A., et al. 2015. Multiplexed, quantitative workflow for sensitive biomarker discovery in plasma yields novel candidates for early myocardial injury. Mol. Cell. Proteomics. 14, 2375–2393.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Gundry R.L., White M.Y., Nogee J., et al. 2009. Assessment of albumin removal from an immunoaffinity spin column: Critical implications for proteomic examination of the albuminome and albumin-depleted samples. Proteomics. 9, 2021–2028.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Camaggi C.M., Zavatto E., Gramantieri L., et al. 2010. Serum albumin-bound proteomic signature for early detection and staging of hepatocarcinoma: Sample variability and data classification. Clin. Chem. Lab. Med. 48, 1319–1326.CrossRefPubMedGoogle Scholar
  8. 8.
    Dowling P., Palmerini V., Henry M., et al. 2014. Transferrin-bound proteins as potential biomarkers for advanced breast cancer patients. BBA Clinical. 2, 24–30.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Hamers-Casterman C., Atarhouch T., Muyldermans S., et al. 1993. Naturally occurring antibodies devoid of light chains. Nature. 363, 446–448.CrossRefPubMedGoogle Scholar
  10. 10.
    Arbabi Ghahroudi M., Desmyter A., Wyns L., et al. 1997. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 414, 521–526.CrossRefPubMedGoogle Scholar
  11. 11.
    Harmsen M.M., De Haard H.J. 2007. Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 77, 13–22.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Muyldermans S., Baral T.N., Retamozzo V.C., et al. 2009. Camelid immunoglobulins and nanobody technology. Vet. Immunol. Immunopathol. 128, 178–183.CrossRefPubMedGoogle Scholar
  13. 13.
    Muyldermans S. 2013. Nanobodies: Natural singledomain antibodies. Annu. Rev. Biochem. 82, 775–797.CrossRefPubMedGoogle Scholar
  14. 14.
    Steeland S., Vandenbroucke R.E., Libert C. 2016. Nanobodies as therapeutics: Big opportunities for small antibodies. Drug Discov. Today. 21, 1077–1113.CrossRefGoogle Scholar
  15. 15.
    Tillib S.V., Ivanova T.I., Vasilev L.A. 2010. Fingerprintlike analysis of “nanoantibody” selection by phage display using two helper phage variants. Acta Naturae. 2, 85–93.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Tillib S., Ivanova T.I., Vasilev L.A., et al. 2013. Formatted single-domain antibodies can protect mice against infection with influenza virus (H5N2). Antiviral Res. 97, 245–254.CrossRefPubMedGoogle Scholar
  17. 17.
    Tillib S.V., Privezentseva M.E., Ivanova T.I., et al. 2014. Single-domain antibody-based ligands for immunoaffinity separation of recombinant human lactoferrin from the goat lactoferrin of trasgenic goat milk. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 949–950, 48–57.CrossRefGoogle Scholar
  18. 18.
    Tillib S.V., Vyatchanin A.S., Muyldermans S. 2014. Molecular analysis of heavy chain-only antibodies of Camelus bactrianus. Biochemistry (Moscow). 79, 1382–1390.CrossRefPubMedGoogle Scholar
  19. 19.
    Page M., Thorpe R. 2002. Purification of IgG by precipitation with sodium sulfate or ammonium sulfate. In: The Protein Protocols Handbook, 2nd ed. Ed. Walker J.M. Totowa, NJ.: Humana Press Inc., pp. 983–984.CrossRefGoogle Scholar
  20. 20.
    Garas M.N., Tillib S.V., Zubkova O.V., et al. 2014. Construction of a pIX-modified adenovirus vector able to effectively bind to nanoantibodies for targeting. Acta Naturae. 6, 95–105.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Larsen M.T., Kuhlmann M., Hvam M.L., Howard K.A. 2016. Albumin-based drug delivery: Harnessing nature to cure disease. Mol. Cell. Ther. 4, 1–12.CrossRefGoogle Scholar

Copyright information

© Pleiades Publishing, Inc. 2017

Authors and Affiliations

  • O. S. Goryainova
    • 1
    • 2
  • T. I. Ivanova
    • 1
  • M. V. Rutovskaya
    • 1
  • S. V. Tillib
    • 1
  1. 1.Institute of Gene BiologyRussian Academy of SciencesMoscowRussia
  2. 2.Department of Immunology, Biological FacultyMoscow State UniversityMoscowRussia

Personalised recommendations